COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) Draft
|
|
- Edwina Baldwin
- 5 years ago
- Views:
Transcription
1 European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 24 April 2008 EMEA/CHMP/BMWP/118264/2007 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) Draft GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL PRODUCTS CONTAINING LOW-MOLECULAR-WEIGHT-HEPARINS FIRST DRAFT March 2007 DRAFT AGREED BY BMWP WORKING PARTY April 2008 ADOPTION BY CHMP FOR RELEASE FOR CONSULTATION April 2008 END OF CONSULTATION (DEADLINE FOR COMMENTS) October 2008 Comments should be provided electronically in word format using this template to KEYWORDS: Low-molecular-weight heparins, similar biological medicinal products, comparability, non-clinical studies, clinical studies, indication, extrapolation 7 Westferry Circus, Canary Wharf, London, E14 4HB, UK Tel. (44-20) Fax (44-20) mail@emea.europa.eu European Medicines Agency, Reproduction is authorised provided the source is acknowledged
2 GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL PRODUCTS CONTAINING LOW-MOLECULAR-WEIGHT-HEPARINS EXECUTIVE SUMMARY INTRODUCTION (background) SCOPE LEGAL BASIS MAIN GUIDELINE TEXT NON-CLINICAL STUDIES CLINICAL STUDIES EXTRAPOLATION OF INDICATION PHARMACOVIGILANCE PLAN...7 REFERENCES (scientific and / or legal)...7 2/7
3 EXECUTIVE SUMMARY This guideline lays down the non-clinical and clinical requirements for low molecular weight heparins (LMWHs) containing medicinal products claiming to be similar to another one already marketed. The non-clinical section addresses the pharmaco-toxicological requirements and the clinical section the requirements for pharmacokinetic, pharmacodynamic, efficacy and safety studies as well as pharmacovigilance aspects. 1. INTRODUCTION (background) Heparin is a highly sulphated and heterogeneous member of the glycosaminoglycan family of carbohydrates consisting of various repeating disaccharide units. The most common disaccharide unit is composed of a 2-O-sulfated α-l-iduronic acid and 6-O-sulfated, N-sulfated α-d-glucosamine, IdoA(2S)-GlcNS(6S). Endogenous heparin is synthesised in the granules of mast cells and possesses the highest negative charge density of all known biological molecules. Heparin that is used for therapeutic purposes is sourced from domestic animals, mainly from porcine intestinal mucosa. Heparin catalyzes the inhibition of several serine proteases of the plasmatic coagulation system by antithrombin (AT). For the binding of heparin to AT a specific pentasaccharide sequence, which contains a 3-O-sulphated glucosamine residue, is important. Upon binding to the enzyme inhibitor antithrombin, heparin causes a conformational change in the antithrombin molecule which results in its active site being exposed for inhibition of activated coagulation factors. Furthermore, heparin acts as a catalytic template to which the inhibitor and activated serine proteases such as thrombin and factors IXa and XIa bind. This effect depends essentially on the number of monosaccharides in the heparin molecule. Heparin molecules containing fewer than 18 monosaccharides do not catalyze inhibition of thrombin but still inactivate factor Xa. Heparin enhances the rate of thrombin antithrombin reaction at least a thousand-fold resulting in a stable 1:1 complex after the serineprotease attacks a specific Arg-Ser peptide bond in the reactive site of antithrombin. In addition, heparin has numerous other plasmatic and cellular interactions, but overall, in comparison with the anticoagulatory effect, the clinical relevance of these interactions is uncertain and insufficiently investigated. Heparin is administered parenterally, as it is degraded when taken orally. It can be injected intravenously or subcutaneously, whereas intramuscular injections should be avoided because of the risk of inducing hematomas. Low molecular weight heparins (LMWHs) are prepared from unfractionated heparin by various chemical or enzymatic depolymerisation processes. Thus, the starting material of LMWHs is of biological origin and the manufacturing process defines the characteristics of the drug substance. The complexity of LMWH results largely from the nature of the starting material (unfractionated Heparin extracted from porcine mucosa), the extraction, the fractionation and the production processes. Several state of the art methods for physico-chemical characterisation of LMWH products are available. However, it is presently not known to which extent the multiple different subfractions contribute to the clinical efficacy of LMWH. A specific LMWH differs from unfractionated heparin and from other LMWHs in its pharmacokinetic and pharmacodynamic properties. As a result of the depolymerisation process they normally contain mainly molecules with less than 18 monosaccharide units. This reduction of molecule size is associated with a loss of thrombin inhibition activity in comparison to standard heparin and a more selective inhibition of Xa. 3/7
4 Due to difficulties in the physical detection of LMWH, conventional pharmacokinetic studies cannot be performed. Instead, the absorption and elimination of LMWHs are studied by using pharmacodynamic tests, including anti-fxa and anti-fiia activity. There are several authorised LMWHs that differ in their source material, manufacturing process, pharmacodynamic properties and therapeutic indications, which include treatment and prophylaxis of deep venous thrombosis and prevention of complications of unstable angina and non-q wave cardiac infarction. The most common adverse reactions of heparins are bleedings, whilst the most serious one is the rarely observed Heparin-induced thrombocytopenia type II (HIT ÌI). This antibody-mediated process is triggered by the induction of antibodies directed against neoantigens of platelet-factor 4 (PF4)- heparin complexes. Binding of those antibody-pf4-heparin complexes activates platelets and generates thrombogenic platelet microaggregates. Patients developing thrombocytopenia are in danger of arterial and venous thromboembolic complications. Although the risks for these adverse reactions seem to be reduced in comparison to unfractionated heparin, it is obligatory to monitor the platelet count regularly in all patients using LMWH and to test for PF4-heparin complex-antibodies in those who develop thrombocytopenia or thromboembolic complications during heparin treatment. In conclusion, the heterogeneity of LMWH is very high, the mode of action is not completely understood and it is uncertain whether the PD markers are representative for the clinical outcome. Thus, the major burden of demonstrating two LMWHs being similar biological medicinal products is on a clinical trial. 2. SCOPE The guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues (EMEA/CPMP/42832/05/) lays down the general requirements for demonstration of the similar nature of two biological products in terms of safety and efficacy. This product specific guidance complements the above guideline and presents the current view of the CHMP on the application of the guideline for demonstration of comparability of two LMWHcontaining medicinal products. 3. LEGAL BASIS Directive 2001/83/EC, as amended in particular in Directive 2001/83/EC Art 10(4) and Part II of the Annex I of Directive 2001/83/EC, as amended. 4. MAIN GUIDELINE TEXT 4.1 NON-CLINICAL STUDIES Before initiating clinical development, non-clinical studies should be performed. Non-clinical studies should be comparative in nature and should be designed to detect differences in pharmacotoxicological response between the similar biological medicinal product and the reference LMWH and not just assess the response per se. The approach taken will need to be fully justified in the nonclinical overview. Pharmacodynamic studies In vtro studies: In order to compare any alterations in activity between the similar biological medicinal product and the reference LMWH, data from a number of comparative bioassays (e.g. for anti-xa and anti-iia activity), many of which may already be available from bioassays submitted as part of the quality dossier, should be provided. Standardised assays (e.g. in accordance with the European Pharmacopoeia) should be used to measure activity. 4/7
5 In vivo studies: The in vivo pharmacodynamic activity of the similar biological medicinal product and the reference LMWH should be quantitatively compared in an appropriate in vivo pharmacodynamic model (e.g. by evaluation of pharmacodynamic markers such as anti-xa and anti-iia activity and TFPI (in extenso). If feasible, these evaluations can be performed as part of the described repeat dose toxicity study. and/or a suitable animal venous or arterial thrombosis model. Toxicological studies Data from at least one repeat dose toxicity study in a relevant species (e.g. the rat) should be provided. Study duration should be chosen in accordance with the intended duration of clinical application, however, should be at least 4 weeks. The study should be performed in accordance with the requirements of the "Note for guidance on repeated dose toxicity" (CPMP/SWP/1042/99). Special emphasis should be laid on the determination of effects on blood coagulation/hemostasis and on potential development of osteoporosis. Data on local tolerance in at least one species should be provided in accordance with the "Note for guidance on non-clinical local tolerance testing of medicinal products" (CPMP/SWP/2145/00). If feasible, local tolerance testing can be performed as part of the described repeat dose toxicity study. Safety pharmacology, reproduction toxicology, mutagenicity and carcinogenicity studies are not routine requirements for non-clinical testing of a similar biological medicinal product containing LMWH. 4.2 CLINICAL STUDIES Pharmacokinetic/Pharmacodynamic studies Due to the heterogeneity of LMWHs conventional pharmacokinetic studies cannot be performed. Instead, the absorption and elimination characteristics of LMWHs should be compared by using pharmacodynamic tests as surrogate markers for PK/PD assessment such as anti-fxa and anti-fiia activity and Tissue Factor Pathway Inhibitor (TFPI) activity. In addition, the ratio of anti-fxa and anti-fiia activity should be compared. Assessment of these PD parameters will provide a fingerprint of the different molecular species. These pharmacodynamic properties of the similar biological medicinal product and the reference product should be compared in a randomized, single dose two way crossover study in healthy volunteers using subcutaneous administration. Equivalence margins should be pre-specified and appropriately justified. The selected dose should be in the sensitive part of the dose-response curve in view of the fact that dose-response curve is not linear and varies for the different indications. Clinical efficacy Since a clear correlation between surrogate PD parameters (antifactor Xa or IIa) and clinical outcome has not been established, a similar biological medicinal product containing LMWH should show equivalent efficacy and safety to a reference product approved in the EU. This therapeutic equivalence should be demonstrated in at least one adequately powered, randomised, double-blind, parallel group clinical trial. In theory, this could be done either in the setting of prevention of venous or arterial thromboembolism, or in the setting of treatment of venous thromboembolism. However, the most sensitive model to detect potential differences in efficacy between the new LMWH and the reference product should be selected. Surgical patients have the highest prevalence of venous thromboembolism (VTE). Furthermore, the vast majority of published trials have been performed in surgical patients with high VTE risk, especially in patients with hip and knee surgery, and thus the knowledge about influence of types of surgery, duration of trials and risks for bleeding is the most accurate for this patient population. 5/7
6 Therefore, it is recommended to demonstrate efficacy in the prevention of VTE in patients undergoing surgery with high VTE risk. Preferably, the trial should be conducted in major orthopaedic surgery such as hip surgery. In this clinical setting, patients with hip fracture should be well represented in the study as they have both high thrombotic risk and high perioperative bleeding risk. The posology and administration should follow European recommendations for prophylaxis with the reference product in patients requiring prolonged VTE prophylaxis. In the VTE-prevention setting, the clinically most relevant endpoint consists of proximal deep vein thrombosis (DVT) pulmonary embolism (PE) and VTE-related death. However, the comparative efficacy and safety of the two products may also be assessed using the surrogate composite endpoint, consisting of total number of thromboembolic events (total DVTs, PE and VTE-related death). Adjudication of VTE events by a central independent and blinded committee of experts is strongly encouraged. The study should follow a strict equivalence design where equivalence margins have to be defined a priori and appropriately justified, primarily on clinical grounds. The study should be powered to show therapeutic equivalence on one of the two recommended endpoints mentioned above. State of art imaging technique should be used for the endpoint assessment. While proximal DVTs could be diagnosed with high specificity and sensitivity using ultrasonography, a clear assessment of distal DVT is only possible by using bilateral venography. Thus, this diagnostic procedure is mandatory in trials including total DVT in the endpoint. The most relevant components of the primary endpoint (in particular in the number of proximal DVTs, PE and deaths) should favourably support the biosimilarity of the two products. Assessment of the primary endpoint should be performed at the time of occurrence of symptoms suggestive of VTE or, in asymptomatic patients, at end of treatment. The overall follow-up should be at least 60 days to detect late thrombotic events. The principles as laid down in the overarching CHMP guideline on Similar Biological Medicinal Products (CHMP/BMWP/42832/2005) should be followed. Clinical safety Even if the efficacy is shown to be comparable, the similar biological medicinal product may exhibit a difference in the safety profile. Prelicensing safety data should be obtained in a number of patients sufficient to determine the adverse effect profiles of the test medicinal product. Care should be given to compare the type, frequency and severity of the adverse reactions between the similar biological medicinal product and the reference products. Usually, comparative safety data from the efficacy trial will be sufficient to provide an adequate premarketing safety database. Major bleeding events and clinically relevant non-major bleeding events should be carefully assessed and documented. A consistent and clinically relevant classification of bleedings should be used. Similar to the efficacy evaluation, the adjudication of bleeding events by a central independent and blinded committee of experts, using pre-specified limits is strongly encouraged. For the detection of immune-mediated type of Heparin-induced Thrombocytopenia (HIT Type II) monitoring of platelet count and an adequate diagnostic procedure in patients developing thrombocytopenia during the trial has to be performed. Liver function testing is recommended. 4.3 EXTRAPOLATION OF INDICATION 6/7
7 Demonstration of comparable efficacy and safety in surgical patients at high risk for VTE as recommended may allow extrapolation to other indications of the reference medicinal product if appropriately justified by the applicant. 4.4 PHARMACOVIGILANCE PLAN Within the authorisation procedure the applicant should present a risk management programme/ pharmacovigilance plan in accordance with current EU legislation and pharmacovigilance guidelines. The risk management plan should particularly include rare serious adverse events of the similar biological medicinal product containing LMWH such as Heparin-induced Thrombocytopenia Type II (HIT Type II). REFERENCES (scientific and / or legal) Directive 2001/83/EC, as amended. Guideline on similar biological medicinal products (CHMP/437/04/draft). Guideline on clinical investigation of medicinal products for prophylaxis of high intra and postoperative venous thromboembolic risk (CPMP/EWP/707/98 Rev. 1 - draft) Concept paper on similar biological medicinal products containing low molecular weight heparins (non)clinical issues. (CHMP/BMWP/496286/2006). Note for guidance on toxicokinetics: A Guidance for assessing systemic exposure in toxicological studies (CPMP/ICH/384/95). Note for guidance on non-clinical locale tolerance testing of medicinal products (CPMP/SWP/2145/00). Guideline on risk management systems for medicinal products for human use (EMEA/CHMP 96286/2005). Note for Guidance on Good Clinical Safety Data Management: Definitions and Standards for Expedited Reporting (CPMP/ICH/377/95). 7/7
COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency London, 19 March 2009 EMEA/CHMP/BMWP/118264/2007 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON NON-CLINICAL AND CLINICAL DEVELOPMENT OF SIMILAR BIOLOGICAL
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use 1 2 3 London, 23 July 2009 EMEA/CHMP/BMWP/301636/2008 4 5 6 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BMWP/94528/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) ANNEX TO GUIDELINE
More informationDRAFT GUIDELINE ON SIMILAR MEDICINAL PRODUCTS CONTAINING RECOMBINANT INTERFERON ALPHA
European Medicines Agency London, 18 October 2007 Doc. Ref. EMEA/CHMP/BMWP/102046/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON SIMILAR MEDICINAL PRODUCTS CONTAINING RECOMBINANT
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BMWP/32775/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) ANNEX TO GUIDELINE ON SIMILAR BIOLOGICAL
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BMWP/42832/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR
More informationGuideline on similar medicinal products containing somatropin. Draft agreed by BMWP March Adopted by CHMP for release for consultation May 2005
28 June 2018 EMEA/CHMP/BMWP/94528/2005 Rev. 1 Committee for Medicinal Products for Human Use (CHMP) Annex to Guideline on similar biological medicinal products containing biotechnology-derived proteins
More informationCOMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP)
European Medicines Agency Evaluation of Medicines for Human Use London, 16 June 2005 EMEA/CHMP/94526/2005 COMMITTEE FOR HUMAN MEDICINAL PRODUCTS (CHMP) ANNEX GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL PRODUCTS
More informationEuropean Medicines Agency
European Medicines Agency London, 5 October 2009 Doc. Ref. EMEA/582443/2008 OVERVIEW OF COMMENTS RECEIVED ON DRAFT GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL PRODUCTS CONTAINING LOW-MOLECULAR-WEIGHT-HEPARINS
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE NON-CLINICAL DEVELOPMENT OF FIXED COMBINATIONS OF MEDICINAL PRODUCTS
European Medicines Agency London, 24 January 2008 Doc. Ref. EMEA/CHMP/SWP/258498/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE NON-CLINICAL DEVELOPMENT OF FIXED COMBINATIONS
More informationGuideline on similar biological medicinal products containing recombinant granulocyte-colony stimulating
1 2 3 26 July 2018 EMEA/CHMP/BMWP/31329/2005 Rev 1 Committee for Medicinal Product for Human Use (CHMP) 4 5 6 7 Guideline on similar biological medicinal products containing recombinant granulocyte-colony
More informationScottish Medicines Consortium
Scottish Medicines Consortium fondaparinux, 2.5mg/0.5ml, solution for injection (Arixtra ) No. (287/06) GlaxoSmithKline 7 July 2006 The Scottish Medicines Consortium has completed its assessment of the
More informationGuideline on similar biological medicinal products containing interferon beta
1 2 3 15 December 2011 EMA/CHMP/BMWP/652000/2010 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 Guideline on similar biological medicinal products containing interferon beta 7 Draft Draft
More informationGuideline on Similar Biological Medicinal Products
1 2 3 22 May 2013 CHMP/437/04 Rev 1 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 Draft 7 Draft agreed by Biosimilar Medicinal Products Working Party and Biologics Working Party March 2013
More informationSession 1 Topics. Vascular Phase of Hemostasis. Coagulation Pathway. Action of Unfractionated Heparin. Laboratory Monitoring of Anticoagulant Therapy
~~Marshfield Labs Presents~~ Laboratory Monitoring of Anticoagulant Therapy Session 1 of 4 Session 1 Topics Review of coagulation and the vascular phase of hemostasis Unfractionated heparin Low molecular
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON THE NON-CLINICAL DEVELOPMENT OF FIXED COMBINATIONS OF MEDICINAL PRODUCTS
European Medicines Agency Pre-Authorisation Evaluation of Medicines for Human Use London, 13 October 2005 Doc. Ref. CHMP/EMEA/CHMP/SWP/258498/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
More informationSYNOPSIS. Clinical Study Report for Study CV Individual Study Table Referring to the Dossier
Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product: Individual Study Table Referring to the Dossier (For National Authority Use Only) Name of Active Ingredient: SYNOPSIS Clinical Study
More informationGuideline on the non-clinical requirements for radiopharmaceuticals
1 2 3 15 November 2018 EMA/CHMP/SWP/686140/2018 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 Draft Draft agreed by Safety Working Party October 2018 Adopted by CHMP for release for consultation
More informationLina Al-Lawama. Rama Al-Ashqar. Malik Al-Zohlof
2 Lina Al-Lawama Rama Al-Ashqar Malik Al-Zohlof Anticoagulant drugs Recap Last lecture we were talking about antiplatelet drugs, we mentioned 5 drugs : Aspirin which is used alone with patents that have
More informationClinical Study Synopsis
Clinical Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website or on the website www.clinicalstudyresults.org hosted by the Pharmaceutical Research and
More informationLondon, 11 October 2006 Doc. Ref. EMEA/CHMP/BWP/271475/2006 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency 1 2 London, 11 October 2006 Doc. Ref. 3 4 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) 5 DRAFT 6 7 GUIDELINE ON POTENCY TESTING OF CELL BASED IMMUNOTHERAPY MEDICINAL
More informationThe Lancet Publishes Results from the Landmark Phase III Rivaroxaban Study RECORD2
News Release Bayer HealthCare AG Corporate Communications 51368 Leverkusen Germany Phone +49 214 30 1 www.news.bayer.com Venous Blood Clot Prevention after Hip Replacement Surgery: The Lancet Publishes
More informationEuropean Medicines Agency Evaluation of Medicines for Human Use
European Medicines Agency Evaluation of Medicines for Human Use London, 22 February 2006 EMEA/CHMP/BWP/49348/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON SIMILAR BIOLOGICAL MEDICINAL
More informationEuropean Medicines Agency Evaluation of Medicines for Human Use COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT
European Medicines Agency Evaluation of Medicines for Human Use London, 27 July 2005 EMEA/CHMP/89249/2004 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT Guideline on the Clinical Investigation
More informationGuideline on core SmPC for human fibrinogen products
23 July 2015 EMA/CHMP/BPWP/691754/2013 Rev 1 Committee for Medicinal Products for Human Use (CHMP) Draft Agreed by Blood Products Working Party 27 November 2013 Adoption by CHMP for release for consultation
More informationANTICOAGULANT THERAPY ANTICOAGULANT THERAPY REVISITED Thrombosis is a complication of underaggressive anticoagulant therapy
ANTICOAGULANT THERAPY REVISITED 2004 or, Which one(s) of these (#$%$#!@#^) drugs should be the one(s) I use, and for what? ANTICOAGULANT THERAPY One of most common treatments in hospital & out 2 nd most
More informationRecommendation on elements required to support the medical plausibility and the assumption of significant benefit for an orphan designation
2 March 2010 EMA/COMP/15893/2009 Final Committee for Orphan Medicinal Products (COMP) Recommendation on elements required to support the medical plausibility and the assumption of significant benefit for
More informationBayer R&D Investor Day 2005
Science For A Better Life HealthCare Bayer R&D Investor 25 December 8, 25 London Bayer R&D Investor 25 BAY 59-7939: A Novel, ral, Direct Factor Xa Inhibitor Frank Misselwitz Head of Therapeutic Area Cardiovascular,
More informationLOW MOLECULAR WEIGHT HEPARIN THE STANDARD VALUE
LOW MOLECULAR WEIGHT HEPARIN THE STANDARD VALUE ANASTASIOS V. KOROMPILIAS, MD ORTHOPAEDIC DEPARTMENT, MEDICAL SCHOOL UNIVERSITY OF IOANNINA, IOANNINA, GREECE MAJOR ORTHOPAEDIC SURGERY POSTOPERATIVE CLASSIFIED
More informationSource of effectiveness data The evidence for effectiveness was based on a synthesis of previously completed studies.
Economic evaluation of the use of nadroparin calcium in the prophylaxis of deep vein thrombosis and pulmonary embolism in surgical patients in Italy Lloyd A, Aitken J A, Hoffmeyer U K, Kelso E J, Wakerly
More informationAdoption by CHMP for release for 3-month public consultation 18 November End of consultation (deadline for comments) 28 February 2011
18 October 2012 EMA/651649/2010 Committee for Medicinal Products for Human Use Reflection paper on considerations given to designation of a single stereo isomeric form (enantiomer), a complex, a derivative,
More informationBevyxxa (betrixaban) NEW PRODUCT SLIDESHOW
Bevyxxa (betrixaban) NEW PRODUCT SLIDESHOW Introduction Brand name: Bevyxxa Generic name: Betrixaban Pharmacological class: Factor Xa inhibitor Strength and Formulation: 40mg, 80mg; caps Manufacturer:
More informationLVHN Scholarly Works. Lehigh Valley Health Network. Joseph G. Ottinger RPh, MS, MBA, BCPS Lehigh Valley Health Network,
Lehigh Valley Health Network LVHN Scholarly Works Department of Pharmacy Retrospective Evaluation of Delayed Administration of Fondaparinux in Providing Comparable Safety and Efficacy Outcomes in Patients
More informationPharmacology Lecture 5. Anticoagulants
Pharmacology Lecture 5 Anticoagulants General overview Anti-thrombotic Drugs Antiplatlets Anticoagulants Fibrinolytics Anticoagulants Indirect Thrombin Inhibitors Anti-thrombotic effect is exerted by interaction
More informationImmunogenicity: Impact on the Design of Clinical Trials for Biosimilars
Immunogenicity: Impact on the Design of Clinical Trials for Biosimilars Alexander Berghout, M.D., Ph.D. Head Global Clinical Research and Development Sandoz Biopharmaceuticals BMWP/BWP Workshop on Immunogenicity
More informationICH CONSIDERATIONS Oncolytic Viruses
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ICH CONSIDERATIONS Oncolytic Viruses 20 November 2008 EMEA/CHMP/GTWP/607698/2008
More informationCOMMITTEE FOR THE MEDICINAL PRODUCT FOR HUMAN USE (CHMP)
European Medicines Agency London, 26 April 2007 Doc. Ref. EMEA/CHMP/GTWP/367513/2006 COMMITTEE FOR THE MEDICINAL PRODUCT FOR HUMAN USE (CHMP) CONCEPT PAPER ON The development of a Guideline on clinical
More informationHIBOR. 1st Prophilaxis. Acute phase treatment. Pentasaccharide. Long-term 2ª ACOs UFH LMWH LMWH LMWH. Competitors
HIBOR Competitors 1st Prophilaxis LMWH Pentasaccharide Long-term Profilaxis treatment 2ª ACOs LMWH Acute phase treatment UFH LMWH Unfractionated heparin (UFH) Discovered by J. Mc Lean in 1916. Later named
More informationMEDICINES CONTROL COUNCIL
MEDICINES CONTROL COUNCIL BIOSIMILAR MEDICINES QUALITY, NON-CLINICAL AND CLINICAL REQUIREMENTS This guideline is intended to provide recommendations to applicants wishing to submit applications for the
More informationUpdate on the new immunogenicity guideline in the EU
Update on the new immunogenicity guideline in the EU draft 2016 EBF, Lisbon 27 th September 2016 Venke Skibeli, Senior Scientist, PhD Norwegian Medicines Agency, Member of the CHMP - BMWP, EMA, London
More informationGuideline for the conduct of efficacy studies for nonsteroidal anti-inflammatory drugs
1 2 3 4 5 6 7 8 8 November 2012 EMA/CVMP/EWP/1061/2001-CONSULTATION Committee for Medicinal Products for Veterinary Use (CVMP) Guideline for the conduct of efficacy studies for nonsteroidal anti-inflammatory
More informationAntithrombotic Therapies: Parenteral Agents
Antithrombotic Therapies: Parenteral Agents Christine A. Sorkness, Pharm.D. Professor of Pharmacy & Medicine (CHS) UW School of Pharmacy Clinical Pharmacist, Anticoagulation Clinic, Wm S. Middleton VA
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Evaluation of Medicines for Human Use London, 29 July 2004 CPMP/BPWG/1089/00 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE CLINICAL INVESTIGATION OF PLASMA
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) CORE SPC FOR HUMAN PLASMA DERIVED ANTITHROMBIN
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 17 January 2002 CPMP/BPWG/3226/99 COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) CORE SPC
More informationAdoption by CHMP for release for 3-month public consultation 18 November End of consultation (deadline for comments) 28 February 2011
18 November 2010 EMA/651649/2010 Committee for Medicinal Products for Human Use Reflection paper on considerations given to designation of a single stereo isomeric form (enantiomer) as new active substance
More informationType of intervention Secondary prevention. Economic study type Cost-effectiveness analysis.
Comparison of the cost of preventing postoperative deep vein thrombosis with either unfractionated or low molecular weight heparin Bergqvist D, Lindgren B, Matzsch T Record Status This is a critical abstract
More informationCOMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP)
The European Agency for the Evaluation of Medicinal Products Evaluation of Medicines for Human Use London, 25 July 2002 EMEA/ COMMITTEE FOR PROPRIETARY MEDICINAL PRODUCTS (CPMP) NOTE FOR GUIDANCE ON THE
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) POSITION PAPER ON NON-CLINICAL SAFETY STUDIES TO SUPPORT CLINICAL TRIALS WITH A SINGLE MICRODOSE
European Medicines Agency Evaluation of Medicines for Human Use London, 23 June 2004 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) POSITION PAPER ON NON-CLINICAL SAFETY STUDIES TO SUPPORT CLINICAL
More informationISIS PHARMACEUTICALS. ISIS-FXI Rx Program Update. Webcast December 8, 2014
ISIS PHARMACEUTICALS ISIS-FXI Rx Program Update Webcast December 8, 2014 Introduction Stan Crooke, M.D., Ph.D. CEO and Chairman, Isis Pharmaceuticals 2 Forward Looking Language Statement This presentation
More informationBiosimilar Monoclonal Antibodies: Registration Requirements. Henry M. J. Leng
Biosimilar Monoclonal Antibodies: Registration Requirements Henry M. J. Leng Disclaimer This presentation is given in my personal capacity and represents only the author s personal views and does not represent
More informationSubmission of comments on Guideline on Similar Biological Medicinal Products (CHMP/437/04 Rev1)
October 31, 2013 Submission of comments on Guideline on Similar Biological Medicinal Products (CHMP/437/04 Rev1) Comments from: Name of organisation or individual Biotechnology Industry Organization (BIO)
More informationBiosimilars in the EU
Biosimilars in the EU Information guide for healthcare professionals Prepared jointly by the European Medicines Agency and the European Commission Table of contents Foreword 2 Summary 3 Biological medicines:
More informationPlatelet Factor IV- Heparin Antibodies. Presenter: Michael J. Warhol, M.D.
Platelet Factor IV- Heparin Antibodies Presenter: Michael J. Warhol, M.D. Learning Objectives Describe the mechanism of interaction between Heparin and Platelet Factor 4 Review the chemistry of Heparin
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON THE CLINICAL INVESTIGATION OF RECOMBINANT FACTOR VIII AND IX PRODUCTS
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 19 July 2007 CPMP/BPWG/1561/99 rev.1 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT GUIDELINE ON THE
More informationa unit of Dr Bharat S Mody Director Chief Arthroplasty Surgeon Centre for Knee & Hip Surgery Dr Pankaj Patni Orthopaedic Surgeon Dr Sunil Dewangan
Centre for Knee & Hip Surgery Arthroscopy a unit of Arthroplasty Dr Bharat S Mody Director Chief Arthroplasty Surgeon Dr Sunil Dewangan Dr Prakash Tekwani Dr Rahul Khanna Dr Pankaj Patni Orthopaedic Surgeon
More information1225 Eye Street NW, Ste. 400 Washington, DC 20005
1225 Eye Street NW, Ste. 400 Washington, DC 20005 30 June 2005 EMEA Biologics Working Party Secretariat Attention: Linda Olsson European Medicines Agency 7 Westferry Circus Canary Wharf London E14 4HB
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 27 April 2006 CPMP/BPWG/575/99 Rev. 1 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) GUIDELINE ON THE CLINICAL
More informationInterested parties (organisations or individuals) that commented on the draft document as released for consultation.
21 February 2013 EMA/92876/2013 Committee for Medicinal Products for Human Use (CHMP) Overview of comments on 'Guideline on non-clinical and clinical development of similar biological medicinal products
More informationNon-clinical Assessment Requirements
Non-clinical Assessment Requirements Presented by: Maria Nieto-Gutierrez Safety and Efficacy of Medicines/Human Medicines Development and Evaluation An agency of the European Union Contents: Relevance
More informationPresentation outline
European Pharmacopoeia Training Session on Biologicals 7-8 February 2017, Strasbourg Heparins and substances of natural origin in the European Pharmacopoeia Gwenael Cirefice Scientific Officer, European
More informationOmar A. Elkashef, MD
DVT Prophylaxis in Orthopedic Surgery By Omar A. Elkashef, MD Kasr Al- aini About VTE Venous thromboembolism encompasses deep vein thrombosis (DVT) and pulmonary embolism VTE is common and PE is a potentially
More informationGuideline for the quality, safety and efficacy of follow-on biological medicinal products
Guideline for the quality, safety and efficacy of follow-on biological medicinal products 1. Introduction A follow-on biological medicinal product (hereinafter referred to as FOBMP) is considered as a
More informationScottish Medicines Consortium
Scottish Medicines Consortium fondaparinux sodium, 2.5mg/0.5ml solution for injection, pre-filled syringe (Arixtra ) No. (420/07) GlaxoSmithKline 09 November 2007 The Scottish Medicines Consortium has
More informationDevelopment of non-substantially manipulated cell-based ATMPs 1 : flexibility introduced via the application of the risk-based approach
3 July 2017 EMA/CAT/216556/2017 Inspections, Human Medicines, Pharmacovigilance and Committees Division Development of non-substantially manipulated cell-based ATMPs 1 : flexibility introduced via the
More informationGuideline on the clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration (SCIg/IMIg)
1 2 3 15 November 2012 EMA/CHMP/BPWP/410415/2011 rev 1 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 7 Guideline on the clinical investigation of human normal immunoglobulin for subcutaneous
More informationRegulatory Perspective
Regulatory Perspective Presented by Dr Maria Isaac MASc, MD, PhD, Pharmaceutical Medicine Physician, Psychiatrist Senior Scientific Officer An agency of the European Union Disclaimer The views expressed
More informationDrugs used in Thromboembolic Disease. Munir Gharaibeh, MD, PhD, MHPE Department of Pharmacology Faculty of Medicine October 2014
Drugs used in Thromboembolic Disease Munir Gharaibeh, MD, PhD, MHPE Department of Pharmacology Faculty of Medicine October 2014 Drugs used in Thromboembolic Disease Anticoagulants: Heparin. Oral anticoagulants.
More informationRegulatory Issues and Drug Product Approval for Biopharmaceuticals
Regulatory Issues and Drug Product Approval for Biopharmaceuticals Vinod P. Shah, Ph. D. FIP Scientific Secretary Biotech 2007 Southern African Regional and International Regulatory Biotechnology Workshop
More informationICH Considerations Oncolytic Viruses ONCOLYTIC VIRUSES (EMEA/CHMP/ICH/607698/2008) TRANSMISSION TO CHMP November 2008
European Medicines Agency October 2009 EMEA/CHMP/ICH/607698/2008 ICH Considerations Oncolytic Viruses ONCOLYTIC VIRUSES (EMEA/CHMP/ICH/607698/2008) TRANSMISSION TO CHMP November 2008 TRANSMISSION TO INTERESTED
More informationPanama City, Panama April, 12-15, Marcelo Mario Matos Moreira. The Brazilian Health Surveillance Agency (ANVISA)
DIA Latin American Regulatory Conference Panama City, Panama April, 12-15, 2011 Biosimilars/Biotechnology Marcelo Mario Matos Moreira Coordinator Office of Biological Products The Brazilian Health Surveillance
More informationJoint MHLW/EMA reflection paper on the development of block copolymer micelle medicinal products
1 2 3 17 January 2013 EMA/CHMP/13099/2013 Committee for Medicinal Products for Human Use (CHMP) 4 5 6 Joint MHLW/EMA reflection paper on the development of block copolymer micelle Agreed by Nanomedicines
More informationManagement of Bleeding in the Anticoagulated Patient Short Snappers CSIM 2015 Elizabeth Zed, MD, FRCPC October 17, 2015
+ Management of Bleeding in the Anticoagulated Patient Short Snappers CSIM 2015 Elizabeth Zed, MD, FRCPC October 17, 2015 + Disclosures Off label use of PCC and apcc will be discussed My centre participates
More informationClinical Study Synopsis
Clinical Study Synopsis This file is posted on the Bayer HealthCare Clinical Trials Registry and Results website or on the website www.clinicalstudyresults.org hosted by the Pharmaceutical Research and
More informationSUBMISSION OF COMMENTS ON The Requirements for First-in-Human Clinical Trials for Potential High Risk Medicinal Products EMEA/CHMP/SWP/28367/2007
European Medicines Agency SUBMISSION OF COMMENTS ON The Requirements for First-in-Human Clinical Trials for Potential High Risk Medicinal Products EMEA/CHMP/SWP/28367/2007 COMMENTS FROM The Biotechnology
More informationfact sheet 3 Introduction to Biosimilars & Regulatory Requirements
3 fact sheet 3 Introduction to Biosimilars & Regulatory Requirements International Alliance of Patients Organizations CAN Mezzanine 49-51 East Road London N1 6AH United Kingdom International Federation
More informationClexane pre-filled syringes 150mg/ml in syringe sizes equating to the following doses: 120mg and 150mg. Page 1 of 8
Low Molecular Weight Heparins (LMWH) Shared Care Guideline for the use of Enoxaparin and Dalteparin in the Treatment and Prophylaxis of Venous Thromboembolism Introduction Low Molecular Weight Heparins
More informationS9 Nonclinical Evaluation for Anticancer Pharmaceuticals
S9 Nonclinical Evaluation for Anticancer Pharmaceuticals This draft guidance, when finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create
More informationiccnet CHSA Clinical Protocol - HEPARIN
Name: iccnet CHSA Clinical Protocol - HEPARIN This clinical guideline or clinical protocol is based on a review of best practice evidence and expert opinion. It is intended to guide practice and does not
More informationBaek, Kyung-min. Recombinant Protein Products Division. Ministry of Food and Drug Safety
Baek, Kyung-min Recombinant Protein Products Division Ministry of Food and Drug Safety About Ministry of Food and Drug Safety Regulation for Biosimilar Principle of Biosimilar Approach Status of Biosimilar
More informationNon-clinical documentation Overview of Requirements
3 rd EMEA-. Non-clinical Aspects Non-clinical documentation Overview of Requirements EMEA Pre-Authorisation Human Unit 3 rd EMEA-. Non-clinical Aspects Outline Overview of Legal and Regulatory requirements
More informationNew Anticoagulants Linda Liu, M.D.
Difficult Task New Anticoagulants Professor UCSF Dept of Anesthesia 15 minutes! Emphasis on 2 new oral anticoagulants Dabigatran Rivaroxaban Relation to anesthesia Rapid reversal Regional anesthesia UC
More information10/8/2013. Drug-induced immune thrombocytopenia (DITP) Clinical aspects
Richard Aster, MD Blood Center of Wisconsin, Blood Research Institute, Milwaukee, WI Senior Investigator Medical College of Wisconsin Professor, Departments of Medicine & Pathology Drug-induced immune
More informationStructure and content of an IMPD. What is required for first into man trial?
What is required for first into man? The EU IMPD Thomas Sudhop, MD Scope Structure and content of an IMPD What is required for first into man trial? Only for IMPs that do not have a marketing authorisation
More informationPersonal Disclosure. The Coagulation Cascade. Learning Objectives. Unfractionated Heparin (UFH): Mechanism of Action. Heparin: Mechanism of Action
Personal Disclosure Heparin/Low Molecular Weight Heparin and Fondaparinux Pharmacology and Pharmacotherapy Mary Jane E. Mattern PharmD Pharmacist William W. Backus Hospital There are no actual or potential
More informationPhysician Orders - Adult
Physician Orders - Adult attach patient label here Title: Direct Thrombin Inhibitor (DTI) Protocol Orders Height: cm Weight: kg Allergies: [ ] No known allergies [ ]Medication allergy(s): [ ] Latex allergy
More informationUvA-DARE (Digital Academic Repository) Factor XI as target for antithrombotic therapy van Montfoort, M.L. Link to publication
UvA-DARE (Digital Academic Repository) Factor XI as target for antithrombotic therapy van Montfoort, M.L. Link to publication Citation for published version (APA): van Montfoort, M. L. (2014). Factor XI
More informationMarilyn Johnston Hemostasis Reference Laboratory Hamilton,Ontario
Marilyn Johnston Hemostasis Reference Laboratory Hamilton,Ontario None Discovered in 1916 Named from the Latin word for liver, hepar 1939, heparin requires a plasma cofactor First used in humans in 1940
More informationEuropean Experience with Similar Medicinal Biological Products
European Experience with Similar Medicinal Biological Products 5th Japanese Biologics forum (JBF) National Institute of Health Sciences (NIHS) Tokyo, 16th January, 2008 P.ZORZI Department for Evaluation
More informationThis paper reviews the potential cost-effectiveness
n reports n Cost-Effectiveness of Rivaroxaban After Total Hip or Total Knee Arthroplasty Louis M. Kwong, MD, FACS Abstract Venous thromboembolism (VTE) following joint replacement surgery represents an
More informationComments and suggestions from reviewer
Comments and suggestions from reviewer Page 1 of 13 Title: WHO Guidelines on the Quality, Safety, and Efficacy of Biological Medicinal Products Prepared by Recombinant DNA Technology: WHO/rDNA_DRAFT/12
More informationImplications for Preclinical and Clinical Programs. Novartis Pharmaceuticals Oncology Business Unit June 2, 2011
EU Biosimilarityi il it Guidance Implications for Preclinical and Clinical Programs Shefali Kakar Novartis Pharmaceuticals Oncology Business Unit June 2, 2011 Biologics are more complex than small molecules
More informationPeer Review Report # 2. Low Molecular Weight Heparins
20 th Expert Committee on Selection and Use of Essential Medicines Peer Review Report # 2 Low Molecular Weight Heparins (1) Does the application adequately address the issue of the public health need for
More informationProcedure for the prescribing and administration of Low Molecular Weight Heparins
Procedure for the prescribing and administration of Low Molecular Weight Heparins Author: Lilian Baxendale Designation: Pharmacist Version: 1c Date: March 2013 Date Approved: 17 th May 2013 Approved By:
More informationKey Aspects of Non-Clinical Pharmacology and Pharmacokinetics in the Evaluation of Safety
Safeguarding public health Key Aspects of Non-Clinical Pharmacology and Pharmacokinetics in the Evaluation of Safety David R Jones (david.jones@mhra.gsi.gov.uk) Expert Pharmacotoxicologist, Medicines and
More informationConcept paper on the development of a guideline on quality and equivalence of topical products
1 2 3 4 5 6 7 8 2 December 2014 EMA/CHMP/QWP/558185/2014 Committee for Medicinal Products for Human use (CHMP) Concept paper on the development of a guideline on quality and equivalence of topical Draft
More informationDirect anticoagulation therapy
Direct anticoagulation therapy Pan-Arab Meeting & Saudi Society of Hematology Dr Ihab Alhemaidi MBBS MRCP(Lond UK) FRCPath. Fellow of the Royal Society of Medicine Consultant Adult hematology/bmt Section
More informationClosed Workshop on biosimilar monoclonal antibodies and immunogenicity of monoclonal antibodies October 2011 Dr Christian K Schneider, MD
Draft guideline on biosimilar monoclonal antibodies Closed Workshop on biosimilar monoclonal antibodies and immunogenicity of monoclonal antibodies October 2011 Dr Christian K Schneider, MD CHMP Biosimilar
More informationEDUCATIONAL COMMENTARY D-DIMER UPDATE
EDUCATIONAL COMMENTARY D-DIMER UPDATE Educational commentary is provided through our affiliation with the American Society for Clinical Pathology (ASCP). To obtain FREE CME/CMLE credits see the Continuing
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Arixtra) Reference Number: CP.PHAR.226 Effective Date: 07.01.18 Last Review Date: 02.18 Line of Business: Oregon Health Plan Coding Implications Revision Log See Important Reminder at
More informationType of intervention Primary prevention. Economic study type Cost-effectiveness analysis.
Cost/death averted with venous thromboembolism prophylaxis in patients undergoing total knee replacement or knee arthroplasty Nerurkar J, Wade W E, Martin B C Record Status This is a critical abstract
More information